Annovis Bio Stock Plummets on Dilutive $10 Million Offering

Annovis Bio shares crater over 30% to a new 52-week low after pricing a discounted $10M public offering to fund its Alzheimer's and Parkinson's drug trials.

Shares of Annovis Bio cratered on Thursday, shedding over 30% to hit a new 52-week low of €1.38. The steep decline was a direct reaction to the company's announcement of a public offering priced at a significant discount, a move designed to fund its pivotal late-stage clinical programs but one that immediately diluted existing shareholders.

The biopharma firm priced its underwritten public offering of shares and warrants, aiming to raise gross proceeds of $10 million. Under the terms, the company is issuing approximately 5.26 million units, each consisting of one share of common stock and one warrant to purchase an additional share. The offering price is set at $1.90 per unit. The attached warrants grant holders the right to buy another share at an exercise price of $2.50, with a term of six months. The transaction is expected to close on Friday, April 10, 2026.

While the financing secures crucial capital, the market's negative response was swift. The stock's plunge to €1.38 marked a fresh low for the past year. Earlier in the session, the equity was trading around €1.73, representing a loss of nearly 13% and approaching its previous 52-week low of €1.70.

Management stated the net proceeds will be used primarily to advance the clinical development of its lead candidate, buntanetap, with remaining funds allocated for general corporate purposes and working capital. The drug is being studied as a potential treatment for neurodegenerative diseases, specifically Alzheimer's and Parkinson's.

On the operational front, Annovis provided updates on its clinical progress. The registrational Phase 3 trial for buntanetap in early Alzheimer's disease has reached approximately 70% of its recruitment target. This study is being conducted across 84 sites in the United States. Separately, an extension study for Parkinson's disease patients is underway, with recruitment currently at about 20%.

These clinical efforts are bolstered by strengthened intellectual property. In early April, the company secured a new patent covering the use of buntanetap for treating neurological injuries resulting from brain infections. This protection extends the drug's potential market exclusivity out to 2044.

The company's leadership structure has seen recent changes, with the Chief Executive Officer assuming the role of interim Chief Financial Officer in March. Investor attention now shifts to upcoming catalysts, including symptomatic efficacy data from the pipeline and the scheduled release of first-quarter 2026 financial results in mid-May. For now, the substantial dilution from the capital raise has overshadowed these clinical milestones, leaving shareholders to weigh near-term financial pain against the drug's long-term potential.